Novo nordisk a/s: european regulatory authority adopts positive opinion for an update of the ozempic® label to reflect risk reduction of kidney disease-related events

BagsvÆrd, denmark, 12 december 2024 – novo nordisk today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion for an update of the ozempic® (once-weekly subcutaneous semaglutide) label to reflect data from the flow kidney outcomes trial. the flow trial assessed the risk reduction from ozempic® therapy in chronic kidney disease-related events, including persistent ≥50% decline in estimated glomerular filtration rate (egfr), onset of persistent egfr
NVO Ratings Summary
NVO Quant Ranking